SREBF1 and hepatocellular carcinoma: Acyl CoA synthetase 4 (ACSL4), and oncogene and marker of the alpha-fetoprotein-high subtype of HCC, upregulates expression of SREBP-1 and downstream lipogenic enzymes to reprogram fatty acid metabolism through c-myc, which facilitates HCC progression [67].